MondegarAI
Rosalind Advisors, Inc.

Q3 2025 · 13F-HR

Rosalind Advisors, Inc.holdings as filed

Filed 2025-11-13 · accession 0001622627-25-000038

$292.6M
Reported value
39
Positions
2025-09-30
Period end
View analyzed profile →PRO

The Brief · Rosalind Advisors, Inc. · Q3 2025

AI · grounded in 13F

Rosalind Advisors, Inc. established a new position in DCTH valued at $33.0M. The fund also initiated new stakes in CYTK for $22.0M and FENC for $19.4M. Additional new positions include VSTM, RZLT, and XERS. The fund ended the period with 39 positions and total AUM of $292.6M.

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
24661P807DCTHDELCATH SYS INC$33.0M11.3%3,300,389CommonSOLE
23282W605CYTKCYTOKINETICS INC$22.0M7.51%400,000CommonSOLE
31447P100FENCFENNEC PHARMACEUTICALS INC$19.4M6.64%2,076,840CommonSOLE
92337C203VSTMVERASTEM INC$17.0M5.82%1,929,563CommonSOLE
76200L309RZLTREZOLUTE INC$17.0M5.81%1,807,202CommonSOLE
98422E103XERSXERIS BIOPHARMA HOLDINGS INC$14.6M5.00%1,795,766CommonSOLE
805111101SVRASAVARA INC$14.3M4.88%4,000,000CommonSOLE
M68830112MDWDMEDIWOUND LTD$13.5M4.61%749,054CommonSOLE
92790C104VRDNVIRIDIAN THERAPEUTICS INC$12.9M4.43%600,000CommonSOLE
156944100CGONCG ONCOLOGY INC$12.1M4.13%300,000CommonSOLE
925050106VRNAVERONA PHARMA PLC$10.7M3.65%100,000CommonSOLE
45166A102IDYAIDEAYA BIOSCIENCES INC$9.5M3.26%350,000CommonSOLE
45779A846NSPRINSPIREMD INC$9.4M3.22%3,905,743CommonSOLE
30233G209EYPTEYEPOINT PHARMACEUTICALS INC$9.3M3.16%650,000CommonSOLE
60255C885BRD1EURMIND MEDICINE MINDMED INC$8.8M3.02%750,000CommonSOLE
23256X407HELPCYBIN INC$8.8M3.02%1,500,000CommonSOLE
35168W103GUTSFRACTYL HEALTH INC$8.0M2.72%5,000,000CommonSOLE
002120202ATYRATYR PHARMA INC$7.6M2.59%1,039,080CommonSOLE
N90064101QUREUNIQURE NV$7.3M2.49%125,000CommonSOLE
98420X202XFORX4 PHARMACEUTICALS INC$5.3M1.81%1,544,607CommonSOLE
67576A100OCULOCULAR THERAPEUTIX INC$4.7M1.60%400,000CommonSOLE
002120952ATYRATYR PHARMA INC$4.5M1.53%1,570,200PUTSOLE
00444T209TLPHTALPHERA INC$3.9M1.34%4,385,757CommonSOLE
74319B502PROFPROFOUND MED CORP$3.4M1.16%692,185CommonSOLE
62857J201MYOMYOMO INC$3.4M1.16%3,790,788CommonSOLE
M8001Q126PYPDPOLYPID LTD$3.1M1.05%918,668CommonSOLE
46090E953QQQINVESCO QQQ TR$1.6M0.53%250,000PUTSOLE
09077D209BFRIBIOFRONTERA INC$1.1M0.38%1,140,764CommonSOLE
04635X102CATBUSDASTRIA THERAPEUTICS INC$1.1M0.38%1,542,520CommonSOLE
78464A950SPDR SERIES TRUST$950,6380.32%2,128,300PUTSOLE
89532M101TRVITREVI THERAPEUTICS INC$915,0000.31%100,000CommonSOLE
92337C903VSTMVERASTEM INC$898,2150.31%646,500CALLSOLE
50127T109KURAKURA ONCOLOGY INC$885,0000.30%100,000CommonSOLE
78462F953SPYSPDR S&P 500 ETF TR$717,5000.25%300,000PUTSOLE
76200L909RZLTREZOLUTE INC$546,3600.19%263,100CALLSOLE
45166A902IDYAIDEAYA BIOSCIENCES INC$236,9400.08%35,900CALLSOLE
76029N906REPLREPLIMUNE GROUP INC$183,1000.06%511,400CALLSOLE
464287955ISHARES TR$20,0000.01%200,000PUTSOLE
80706P953SRRKSCHOLAR ROCK HLDG CORP$10,0000.00%100,000PUTSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.